Guardant Health Shares Jump 4.58% on Q2 Revenue Growth Product Expansion and Analyst Upgrades Trading Volume Ranks 495th

On August 29, 2025, Guardant Health (GH) saw a 4.58% rise in its stock price, with trading volume reaching $180 million—a 103.51% increase from the prior day—ranking it 495th in market activity. The surge followed a series of strategic and financial updates that bolster investor confidence in the liquid biopsy leader.

Guardant reported a 31% year-over-year revenue growth in Q2 2025, driven by strong performance across its oncology, screening, and biopharma segments. The company raised its full-year revenue guidance to $915–$925 million, reflecting a projected 24–25% growth. Analysts from Scotiabank and TD Cowen raised their price targets to $60–$63, citing the Q2 results and expanded product offerings. Notably, Guardant360 Liquid biopsy launched 11 new applications, enhancing its competitive edge in non-invasive cancer detection.

A strategic partnership with actor James Van Der Beek to promote early colorectal cancer screening via the Shield blood test further amplified the company’s market visibility. Despite a 90.4% gross margin in Q2, the firm continues to operate at a net loss, with negative EBIT and EBITDA margins. However, its cash reserves exceed $105 million, providing flexibility for operational needs and strategic investments.

Backtest results indicate that Guardant’s stock exhibited a 4.3% intraday gain on August 29, aligning with the 4.58% closing price increase. The stock’s performance was driven by strong revenue growth, product expansion, and analyst upgrades, while its cash position and strategic collaborations underscored long-term resilience despite ongoing profitability challenges.